Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

137.57 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,954
Open 137.57
Bid (Size) 135.66 (4)
Ask (Size) 135.73 (5)
Prev. Close 137.57
Today's Range 137.57 - 137.57
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Novo Nordisk
Via Benzinga

Performance

YTD
+34.73%
+34.73%
1 Month
-2.34%
-2.34%
3 Month
+3.40%
+3.40%
6 Month
+12.99%
+12.99%
1 Year
+49.01%
+49.01%

More News

Read More
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Via The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Via The Motley Fool
Topics Earnings
Exposures Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Via Benzinga
Exposures Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
Via Benzinga
3 Stable Blue-Chip Stocks to Buy for the Market Storm
Via InvestorPlace
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
Via The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
Via Investor's Business Daily
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Via InvestorPlace
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
Via The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
Via The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
Via The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Via MarketBeat
Topics ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Via The Motley Fool
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Via MarketBeat
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
Via The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
Via The Motley Fool
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.